Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May;27(5):479-486.
doi: 10.1002/pds.4291. Epub 2017 Aug 16.

Characterization of opioid use in sickle cell disease

Jin Han  1   2   3 , Jifang Zhou  2 , Santosh L Saraf  3 , Victor R Gordeuk  3 , Gregory S Calip  2   4
Affiliations

Characterization of opioid use in sickle cell disease

Jin Han et al. Pharmacoepidemiol Drug Saf. 2018 May.

Abstract

Purpose: Opioid analgesics are commonly used to treat vaso-occlusive pain episodes in sickle cell disease (SCD), but comprehensive evidence characterizing opioid use in this patient population is limited. Our objective was to characterize opioid use patterns among SCD patients using a large nationwide database.

Methods: A large, US medical claims database was utilized to identify a cohort of 3882 SCD patients, and characteristics of opioid use were analyzed. Clinical variables including age, gender, medication use, health care utilization, and medical history were evaluated for correlations with opioid use.

Results: Forty percent of patients took opioid medications during a 12-month span, and the prevalence of any opioid use was highest for 20 to 29-year-old patients (58%). The median daily opioid dose was 1.85 mg (interquartile range: 0.62-10.68 mg) oral morphine equivalents (OME). While most opioid users took between 0 and 5 mg OME daily, 3% of pediatric patients and 23% of adult patients used more than 30-mg OME daily. High-dose opioid use was associated with older age, hydroxyurea therapy, nonsteroidal anti-inflammatory drug (NSAID) use, and frequent inpatient hospitalizations. In multivariable-adjusted analyses, patients with vaso-occlusive complications such as pain crisis (OR = 3.8, 95% CI 2.7-5.3) and avascular necrosis (AVN) (OR = 3.7, 95% CI 2.7-5.1) were associated with high-dose opioid use.

Conclusions: Our study showed that only 40% SCD patients were on opioid analgesics during a 12-month span. However, a non-trivial number of patients used a much higher dose of opioids despite a relatively low average daily opioid dose among SCD patients, particularly with vaso-occlusive complications.

Keywords: avascular necrosis; opioid use; pain crisis; sickle cell disease; vaso-occlusive complications.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors declare no conflicts of interest

Figures

Figure 1
Figure 1
Flow-chart of patient inclusion in the study.
Figure 2
Figure 2
Frequency of opioid use in the SCD patients.
Figure 3
Figure 3
Proportion of opioid prescriptions among SCD patients.
See this image and copyright information in PMC

References

    1. Steinberg MH. Management of sickle cell disease. N Engl J Med. 1999;340:1021–30. - PubMed
    1. Hassell KL. Population estimates of sickle cell disease in the US. Am J Prev Med. 2010;38:S512–21. - PubMed
    1. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008;86:480–7. - PMC - PubMed
    1. Lanzkron S, Carroll CP, Haywood C., Jr The burden of emergency department use for sickle-cell disease: an analysis of the national emergency department sample database. Am J Hematol. 2010;85:797–9. - PMC - PubMed
    1. Han J, Saraf SL, Zhang X, et al. Patterns of opioid use in sickle cell disease. Am J Hematol. 2016;91:1102–6. - PMC - PubMed

Publication types

MeSH terms

Substances